The purpose of this study is to establish the maximum tolerated dose (MTD) and recommended
phase 2 dose (RP2D) of OBI-999 as monotherapy, and to characterize the safety and preliminary
clinical activity profile of the RP2D of OBI-999 in patients with advanced solid tumors.
1. Male or female patients, 18 years of age or older at the time of consent.
2. Provide written informed consent prior to performing any study related procedure.
3. Histologically or cytologically confirmed patients with advanced solid tumors.
4. Patients must have been treated with established standard-of-care therapy, or
physicians have determined that such established therapy is not sufficiently
efficacious, or patients have declined to receive standard-of-care therapy. In the
latter case, the informed consent must state the effective therapies the patient is
5. Measurable disease (i.e., at least one measurable lesion per RECIST 1.1)
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
7. Adequate organ function defined as:
i. Serum ALT ≤3 × upper limit of normal (ULN), ≤5 × ULN in the presence of liver
ii. Serum AST ≤3 × ULN, ≤5 × ULN in presence of liver metastases
iii.Serum bilirubin ≤1.5 × ULN (unless due to Gilbert's syndrome or hemolysis)
i. Creatinine clearance >50 mL/minute using Cockcroft Gault equation
i. Absolute neutrophil count ≥1,500/µL
ii. Platelets ≥100,000/µL
iii. Hemoglobin ≥8 g/dL
8. Patient is willing and able to comply with all protocol required assessments, visits,
and procedures, including a pretreatment tumor biopsy. Archival tumor biopsies are
acceptable at baseline.
9. Females of childbearing potential must have negative serum pregnancy test prior to
starting study therapy, and agree to use a reliable form of contraceptive during the
study treatment period and for at least 120 days following the last dose of study
Patient not of childbearing potential (i.e., permanently sterilized, postmenopausal)
can be included in study. Postmenopausal is defined as 12 months with no menses
without an alternative medical cause.
Male patients must agree to use an adequate method of contraception during the study
treatment period and for at least 120 days following the last dose of study drug.
10. Cannot be breast feeding.
11. Patients with human immunodeficiency virus (HIV) infection are eligible if CD4+ T cell
counts ≥ 350 cells/uL; patients on antiretroviral therapy (ART) should be on an
established dose for at least 4 weeks and have an HIV viral load less than 400
copies/mL prior to enrollment.
12. Patients with serological evidence of chronic hepatitis B virus (HBV) infection are
eligible if they have an HBV viral load below the limit of quantification with or
without concurrent viral suppressive therapy.
13. Patients with a history of hepatitis C virus (HCV) infection should have completed
curative antiviral treatment and have a viral load below the limit of quantification.
14. Patients in Part B (Cohort-Expansion) must have documented Globo H H score of at least
100 from a qualified laboratory IHC assay in one of the sponsor-selected tumor types
to be enrolled in the respective cohort:
1. Less than 3 weeks from prior cytotoxic chemotherapy or radiation therapy; and less
than 5 half-lives or 6 weeks, whichever is shorter, from prior biologic therapies,
prior to the first dose of OBI 999.
2. Has undergone a major surgical procedure (as defined by the Investigator) or
significant traumatic injury within 28 days prior to the first dose of OBI 999.
3. Sensory or motor neuropathy of Grade 1 or greater.
4. Patients with a history of solid organ transplant.
5. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to
Grade 0 or 1 (using NCI CTCAE version 5.0), except for alopecia and laboratory values
listed in the inclusion criteria.
6. Receipt of any prior therapy targeting Globo H.
7. Known hypersensitivity to OBI 999 or its excipients.
8. Has known untreated central nervous system metastases. Patients with treated brain
metastases are eligible if there is no evidence of progression for at least 4 weeks
after CNS-directed treatment, as ascertained by clinical examination and brain imaging
(magnetic resonance imaging [MRI] or computed tomography [CT]) during the screening
9. Has a significant clinical cardiac abnormality (e.g., clinical heart failure, unstable
angina, or ejection fraction < 35%)
10. Any medical co morbidity that is life threatening or, in the opinion of the
Investigator, renders the patient unsuitable for participation in a clinical trial due
to possible noncompliance, would place the patient at an unacceptable risk and/or
potential to affect interpretation of results of the study.
11. Is receiving any concurrent prohibited medication